Oxford BioMedica PLC (OXBDF)

[marcusl2]

Oxford Biomedica PLC Publication in the Journal Nature Communications
Commenting on the publication, John Dawson, Chief Executive Officer of Oxford BioMedica, said: "The data published demonstrates Oxford BioMedica's innovative capabilities and our commitment to invest in our technology to maintain our leading position in vector manufacture for gene therapy products. As demand for vectors grows with the introduction of gene and cell therapy products, we are confident there will be significant demand from third parties to licence the rights to utilise our TRiP technology."

-Ends-
http://uk.advfn.com/stock-market/london/oxford-biomedica-OXB/share-news/Oxford-Biomedica-PLC-Publication-in-the-Journal-Na/74187902